From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative-Reference-Cited by-同舟云学术

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative

Published:2021-02 Issue:2 Volume:6 Page:88-89
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Verma Ajay M,Patel Anusha,Subramanian Sreedhar,Smith Philip J

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference2 articles.

1. A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's disease and ulcerative colitis;Ben-Horin;J Crohns Colitis,2020

2. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic;Kennedy;Gut,2020

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous versus intravenous infliximab therapy – a real-world study: toward higher drug concentrations;European Journal of Gastroenterology & Hepatology;2024-08-19

2. A Practical Approach to Subcutaneous Infliximab (Zymfentra);American Journal of Gastroenterology;2024-04-30

3. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?;Internal Medicine Journal;2024-01-12

4. Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study;Alimentary Pharmacology & Therapeutics;2023-11-30

5. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: From conventional to cutting edge in biologics and RNA- based nanomedicines;Advanced Drug Delivery Reviews;2023-10